Nanomedicine for the eradication of Helicobacter pylori: recent advances, challenges and future perspective

Abstract

Helicobacter pylori infection is linked to gastritis, ulcers and gastric cancer. Nanomedicine offers a promising solution by utilizing nanoparticles for precise drug delivery, countering antibiotic resistance and delivery issues. Nanocarriers such as liposomes and nanoparticles enhance drug stability and circulation, targeting infection sites through gastric mucosa characteristics. Challenges include biocompatibility, stability, scalability and personalized therapies. Despite obstacles, nanomedicine’s potential for reshaping H. pylori eradication is significant and showcased in this review focusing on benefits, limitations and future prospects of nanomedicine-based strategies.

Plain language summary

Helicobacter pylori is associated with stomach problems like gastritis, ulcers and cancer. The use of tiny particles, called nanomedicine, may help to precisely deliver drugs to treat these bacterial infections. Using nanomedicine can help to combat drug resistance and drug-delivery issues by making drugs more stable and specifically targeting the infection site. However, there are challenges such as making sure it is safe, stable and can be scaled up for many people. This review discusses the potential of nanomedicine to fight H. pylori infection, its advantages and disadvantages, and how it could be used in the future.

Tweetable abstract

Helicobacter pylori infection links to gastritis, ulcers and cancer. Nanomedicine has the potential to be used in H. pylori eradication, as explored in this review.

Keywords: :

• antibiotic resistance
• H. pylori infections
• Helicobacter pylori
• nanomedicine

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.tandfonline.com/doi/suppl/10.2217/fmb-2023-0189

Financial disclosure

The authors have no financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.